About: Clinical Therapeutics in Hong Kong

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical Therapeutics in Hong Kong Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Clinical Therapeutics in Hong Kong
Creator	Cheung, Bernard Yau, Henry
source	Elsevier; Medline; PMC
abstract	Abstract Hong Kong is a compact territory in Southern China that enjoys a high degree of autonomy. Despite its dense population and uneven wealth distribution, infant mortality is low and life expectancy is long. The health service is more hospital and clinic based than community based. This seems cost-effective while professional standards are high and rigorously maintained. Drug registration follows American and European requirements. Hong Kong is a part of the Pharmaceutical Inspection Cooperation Scheme, which brings a high standard of drug regulation. Hong Kong is a good choice for clinical trials because the subjects are Chinese and protocols in English do not need to be translated. There are also 2 well-established clinical trials centers in university hospitals that also run Phase I and clinical pharmacology studies.
has issue date	2019-03-31(xsd:dateTime)
bibo:doi	10.1016/j.clinthera.2019.01.002
bibo:pmid	30709611
has license	els-covid
sha1sum (hex)	b4725ff88fa414242e8e6fd1742d9c7b37518ccd
schema:url	https://doi.org/10.1016/j.clinthera.2019.01.002
resource representing a document's title	Clinical Therapeutics in Hong Kong
has PubMed Central identifier	PMC7172533
has PubMed identifier	30709611
schema:publication	Clinical Therapeutics
resource representing a document's body	covid:b4725ff88fa414242e8e6fd1742d9c7b37518ccd#body_text
is schema:about of	named entity 'European' named entity 'degree' named entity 'subjects' named entity 'clinical pharmacology' named entity 'Despite' named entity 'registration' named entity 'MAINTAINED' named entity 'TRANSLATED' named entity 'DRUG' named entity 'SUBJECTS' named entity 'HONG KONG' named entity 'HOSPITAL' named entity 'COMPACT' named entity 'DO NOT' named entity 'STANDARD' named entity 'FOLLOWS' named entity 'UNIVERSITY HOSPITALS' covid:arg/b4725ff88fa414242e8e6fd1742d9c7b37518ccd named entity 'professional' named entity 'autonomy' named entity 'university hospitals' named entity 'clinical trials' named entity 'clinical trials' named entity 'health service' named entity 'Hong Kong' named entity 'Hong Kong' named entity 'Pharmaceutical' named entity 'university hospitals' named entity 'Clinical Therapeutics' named entity 'China' named entity 'infant mortality' named entity 'International Council for Harmonisation' named entity 'Western' named entity 'CFDA' named entity 'sovereignty' named entity 'Hong Kong' named entity 'central government in Beijing' named entity 'international organization' named entity 'GMP standards' named entity 'mainland China' named entity 'acute promyelocytic leukemia' named entity 'special administrative region' named entity 'official language' named entity 'board certification' named entity 'Hong Kong' named entity 'Hong Kong Hospital Authority' named entity 'Hong Kong' named entity 'gross domestic product per capita' named entity 'health service' named entity 'multinational' named entity 'bioavailability' named entity 'income tax' named entity 'United States' named entity 'Hong Kong' named entity 'customs duties' named entity 'Japan' named entity 'Hong Kong' named entity 'health care' named entity 'Canada' named entity 'mainland China' named entity 'bioequivalence' named entity 'accelerated approval' named entity 'Chinese ethnicity' named entity 'Pharmaceutical Products' named entity 'health care' named entity 'Hong Kong' named entity 'electoral reform' named entity 'Hong Kong' named entity 'mainland China' named entity 'international community' named entity 'randomized controlled trials' named entity 'Hong Kong' named entity 'broad-spectrum antibiotics' named entity 'infant mortality rates' named entity 'Hong Kong Chinese' named entity 'carbamazepine' named entity 'Hong Kong' named entity 'Chinese' named entity 'biosimilar' named entity 'United States'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software